|
Price: $57.7300
$-0.56 
-0.961%
|
| Day's High:
| $58.96
| Week Perf:
| -1.13 %
|
| Day's Low: |
$ 57.05 |
30 Day Perf: |
-15.45 % |
| Volume (M): |
3,361 |
52 Wk High: |
$ 170.47 |
| Volume (M$): |
$ 194,048 |
52 Wk Avg: |
$99.01 |
| Open: |
$57.90 |
52 Wk Low: |
$55.70 |
|
|
| Market Capitalization (Millions $) |
22,168 |
| Shares
Outstanding (Millions) |
384 |
| Employees |
5,600 |
| Revenues (TTM) (Millions $) |
5,050 |
| Net Income (TTM) (Millions $) |
-5,867 |
| Cash Flow (TTM) (Millions $) |
-1,342 |
| Capital Exp. (TTM) (Millions $) |
738 |
Moderna Inc
Moderna Inc. is a biotechnology company that specializes in the development of messenger RNA (mRNA) therapeutics and vaccines. It was founded in 2010 and is headquartered in Cambridge, Massachusetts.
The company is at the forefront of the mRNA technology, which essentially involves using mRNA to instruct cells in the body to produce therapeutic proteins or stimulate an immune response against specific diseases. This approach has gained significant attention and recognition, especially during the COVID-19 pandemic, as Moderna successfully developed one of the first mRNA-based vaccines against the virus.
In addition to COVID-19, Moderna is actively involved in the development of mRNA vaccines and therapies targeting a range of other diseases, including influenza, Zika virus, and various types of cancer. The company's pipeline includes multiple candidates in different stages of development, demonstrating its commitment to advancing mRNA technology for various medical applications.
Moderna has established collaborations with pharmaceutical companies, government organizations, and academic institutions to enhance its research capabilities and expedite the development of its therapies and vaccines. The company has also made significant investments in manufacturing facilities to support large-scale production of its products.
As of 2021, Moderna has emerged as a leading player in the field of mRNA therapeutics and vaccines, with its COVID-19 vaccine receiving emergency use authorizations and playing a crucial role in the global vaccination efforts. The company continues to focus on advancing the potential of mRNA technology to address various diseases, and its innovative approach has positioned it as a key contributor to the future of biotechnology.
Company Address: 325 Binney Street Cambridge, 2142 MA
Company Phone Number: 714-6500 Stock Exchange / Ticker: NASDAQ MRNA
|
|
|
|
|
|
|
| Stock Performances by Major Competitors |
|
|
|
| Announcement
Published Thu, Sep 5 2024 4:04 PM UTC
'Moderna Investors Urged to Act: Key Deadline Approaches in High-Stakes Securities Class Action'In the fast-paced world of finance, where critical decisions hinge upon timely information, the legal landscape often serves as a battleground for investors seeking justice. In a recent announcement, the Rosen Law Firm??a globally recognized entity devoted to protecting investor r...
|
| Announcement
Published Sat, Aug 24 2024 8:27 PM UTC
In an era marked by unprecedented fluctuations in the pharmaceutical sector and heightened investor scrutiny, Rosen Law Firm, a preeminent global investor rights law firm, has issued a call for action directed at investors of Moderna, Inc. (NASDAQ: MRNA). The firm has urged individuals who purchased securities of Moderna between January 18, 2023, and June 25, 2024, to secure...
|
| Moderna Inc
As the financial results for the first quarter of 2024 for Moderna Inc. were announced, there were a few concerning numbers that caught the attention of investors and analysts. The company slipped into a deficit of $-3.07 per share, a significant decrease from the $0.19 per share profit in the previous year. Additionally, the income per share fell from $0.57 to an undisclosed number from the preceding reporting season. The revenue also took a massive hit, dropping by a staggering -91.031% to $167.00 million from $1.86 billion in the similar reporting season a year ago. Furthermore, there was a sequential revenue tumble of -94.059% from $2.81 billion.
These numbers, no doubt, raised concerns among investors and analysts. However, it is essential to set these results into context and understand the larger picture. Moderna Inc. recently announced a groundbreaking collaboration with Blackstone Life Sciences, which will provide up to $750 million to support Moderna's efforts in developing mRNA vaccines targeting respiratory illnesses, like the flu. This development and commercialization funding agreement signifies a significant milestone in the biotechnology and pharmaceutical industry.
|
| Financing Agreement
Published Wed, Mar 27 2024 10:34 AM UTC
In an exciting development within the biotechnology and pharmaceutical industry, Blackstone Life Sciences (Blackstone) has announced a groundbreaking collaboration with Moderna, Inc. (Moderna) to support the latter's influenza (flu) program. Under a new development and commercialization funding agreement, Blackstone will provide up to $750 million to fuel Moderna's...
|
| Moderna Inc
Moderna Inc, a biotechnology company specializing in mRNA technology, has experienced a significant decline in its financial performance for the fiscal year ending December 31, 2023. The company's income fell sharply by -84.88% per share compared to the previous year, with a net profit per share turning positive from the previous quarter. Revenue also took a hit, fading by -44.709% to $2.81 billion from $5.08 billion in the same quarter a year ago.
Despite these challenges, Moderna Inc is not alone in facing financial difficulties. The rest of the Biotechnology & Pharmaceuticals industry also recorded a top-line gain in the fourth quarter of 2023. Net earnings for Moderna Inc fell by -85.19% from the previous year, highlighting the tough operating environment the company is navigating.
|
| Per Share |
Current |
| Earnings (TTM) |
-15.36 $ |
| Revenues (TTM) |
13.15 $
|
| Cash Flow (TTM) |
- |
| Cash |
22.1 $
|
| Book Value |
30.5 $
|
| Dividend (TTM) |
0 $ |
|
|
| Per Share |
|
| Earnings (TTM) |
-15.36 $
|
| Revenues (TTM) |
13.15 $ |
| Cash Flow (TTM) |
- |
| Cash |
22.1 $
|
| Book Value |
30.5 $ |
| Dividend (TTM) |
0 $ |
|
|
| |
| Grant revenue |
|
 8.3 % |
of total Revenue |
| Collaboration revenue |
|
2.9 % |
of total Revenue |
| Licensing and royalty revenue |
|
12.45 % |
of total Revenue |
| Total other revenue |
|
23.65 % |
of total Revenue |
|
|
